Short Duration Levetiracetam to Extended Course for Seizure Prophylaxis After aSAH

Not Applicable

Completed

• Conditions: Subarachnoid Hemorrhage

• Registration Number: NCT01137110
• Lead Sponsor: Washington University School of Medicine

Brief Summary

Our primary objective is to compare two treatment options for prevention of seizures following a subarachnoid hemorrhage and determine if a short-course regimen of levetiracetam is as efficacious in the prevention of in-hospital seizures when compared to an extended course.

Detailed Description

This is a prospective, single-center, randomized, controlled trial. Patients admitted with spontaneous SAH (and meet enrollment criteria) will be randomized to either levetiracetam 1000 mg twice daily for 3 days or levetiracetam 1000mg twice daily until hospital discharge.

Study Timeline

• Study Start: 2010-05-01
• Study First Submitted: 2010-05-28
• Study First Submitted QC: 2010-06-03
• Study First Posted: 2010-06-04
• Primary Completion: 2013-01-01
• Study Completion: 2017-01-01
• Results First Submitted: 2018-01-30
• Status Verified: 2019-04
• Results First Submitted QC: 2019-04-29
• Last Update Submitted: 2019-04-29
• Results First Posted: 2019-07-12
• Last Update Posted: 2019-07-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 84

Inclusion Criteria

1. Age >18 years of age
2. Diagnosis of spontaneous SAH

Exclusion Criteria

1. SAH secondary to trauma or arteriovenous malformation
2. Early death (defined as death within 3 days of presentation)
3. Known allergy to levetiracetam
4. Know seizure history on chronic AEDs
5. Pregnancy
6. Current incarceration

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
In-hospital Seizures	from hospital admission to hospital discharge	from admission to In-hospital seizures after aSAH

Trial Locations

Locations (1)

Barnes-jewish Hospital; 🇺🇸 Saint Louis, Missouri, United States